Table 1.
Baseline Demographics of TAILORx cohort with endocrine therapy start within 1 year and 3 weeks of study entry.
| Characteristics | N=9,475 |
|---|---|
| Study Arms, n (%) | |
| Arm A (RS 0-10, assigned endocrine therapy) | 1,577 (16.6%) |
| Arm B (RS 11-25, randomized to endocrine therapy) | 3,361 (35.5%) |
| Arm C (RS 11-25, randomized to endocrine therapy + chemotherapy) | 3,221 (34.0%) |
| Arm D (RS 26-100, assigned endocrine therapy + chemotherapy) | 1,316 (13.9%) |
| Receipt of Chemotherapy, n (%) | |
| Arm C or D, Received Chemo | 3894 (41.1%) |
| Arm C or D, No Chemotherapy * | 643 (6.8%) |
| Arm A or B, Received Chemotherapy * | 188 (2.0%) |
| Arm A or B, No Chemotherapy received | 4750 (50.1%) |
| Mean age (SD), year | 55.6 (9.1) |
| Race, n (%) | |
| White | 7,992 (84.3%) |
| Black | 668 (7.1%) |
| Asian | 398 (4.2%) |
| Other/Not Specified | 417 (4.4%) |
| Ethnicity, n (%) | |
| Hispanic | 861 (9.1%) |
| Not Hispanic | 7,445 (78.6%) |
| Not specified | 1169 (12.3%) |
| Insurance status, n (%) | |
| Private | 5,491 (58.0%) |
| Medicare | 1,104 (11.7%) |
| Medicaid | 549 (5.8%) |
| Military/VA | 82 (0.9%) |
| None (self-pay) | 360 (3.8%) |
| International | 1814 (19.1%) |
| Other/Unknown | 75 (0.8%) |
| Neighborhood Deprivation Index (NDI, value range), n (%) | |
| Quartile 1, highest deprivation (≤ 51.53) | 1,907 (20.1%) |
| Quartile 2 (51.54-53.53) | 1,846 (19.5%) |
| Quartile 3 (53.54-56.48) | 1,873 (19.8%) |
| Quartile 4, lowest deprivation (> 56.48) | 1,873 (19.8%) |
| US zip code unknown or US territory (Puerto Rico) | 162 (1.7%) |
| International | 1,814 (19.1%) |
| Menopausal Status, n (%) | |
| Premenopausal | 3,202 (33.8%) |
| Postmenopausal | 6273 (66.2%) |
| Tumor size in the largest dimension, n (%) | |
| <=2cm | 7,085 (74.8%) |
| > 2cm | 2388 (25.2%) |
| Histologic grade of tumor, n (%) | |
| Low | 2,441 (25.8%) |
| Intermediate | 5132 (54.2%) |
| High | 1620 (17.1%) |
| Unknown | 282 (2.9%) |
| Progesterone receptor expression, n (%) | |
| Negative | 914 (9.6%) |
| Positive | 8,357 (88.2%) |
| Unknown | 204 (2.2%) |
| Oncotype Dx Recurrence Score (RS), n (%) | |
| <= 10 | 1577 (16.6%) |
| 11-25 | 6582 (69.6%) |
| > 25 | 1316 (13.8%) |
| First Endocrine Therapy, n (%) | |
| AI | 5546 (58.5%) |
| Tamoxifen | 3576 (37.7%) |
| Tamoxifen & AI | 68 (0.7%) |
| Ovarian Function Suppression | 249 (2.6%) |
| Other | 36 (0.4%) |
*
reflects patients who did not adhere to assigned treatment arm